Drugs / Autologous Umbilical Cord Blood Mononuclear Cells
Autologous Umbilical Cord Blood Mononuclear Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05138276 | Sep 2021 → Dec 2022 | perinatal necrotizing enterocolitis | Guangdong Women and Children Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03053076 | Feb → May 2017 | — | Guangdong Women and Children Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04311476 | Jul 2018 → Jan 2020 | bronchopulmonary dysplasia | yangjie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Umbilical Cord Blood Mononuclear Cells | “Autologous Umbilical Cord Blood Mononuclear Cells --25 million cells/kg, 48 hours after birth.” NCT03053076 ↗2“Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC” NCT05138276 ↗ “Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy” NCT04311476 ↗ |
| Known as | ACBMNCs | “single intravenous infusion of autologous cord blood MNCs (ACBMNCs)” NCT05138276 ↗ |
| Known as | autologous cord blood MNCs | “single intravenous infusion of autologous cord blood MNCs (ACBMNCs)” NCT05138276 ↗ |
| Modality | Cell therapy | “receive intravenous ACBMNC infusion (5 × 107 cells/kg) or placebo (normal saline)” PMID 32300579 ↗ Apr 2020 |
| Route | Intravenous | “will receive intravenous doses of Autologous Umbilical Cord Blood Mononuclear Cells” NCT03053076 ↗ |